Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 289

1.

Intensity-modulated radiation therapy for pediatric medulloblastoma: early report on the reduction of ototoxicity.

Huang E, Teh BS, Strother DR, Davis QG, Chiu JK, Lu HH, Carpenter LS, Mai WY, Chintagumpala MM, South M, Grant WH 3rd, Butler EB, Woo SY.

Int J Radiat Oncol Biol Phys. 2002 Mar 1;52(3):599-605.

PMID:
11849779
2.

Ototoxicity evaluation in medulloblastoma patients treated with involved field boost using intensity-modulated radiation therapy (IMRT): a retrospective review.

Vieira WA, Weltman E, Chen MJ, da Silva NS, Cappellano AM, Pereira LD, Gonçalves MI, Ferrigno R, Hanriot RM, Nadalin W, Odone Filho V, Petrilli AS.

Radiat Oncol. 2014 Jul 21;9:158. doi: 10.1186/1748-717X-9-158.

3.

Ototoxicity after intensity-modulated radiation therapy and cisplatin-based chemotherapy in children with medulloblastoma.

Paulino AC, Lobo M, Teh BS, Okcu MF, South M, Butler EB, Su J, Chintagumpala M.

Int J Radiat Oncol Biol Phys. 2010 Dec 1;78(5):1445-50. doi: 10.1016/j.ijrobp.2009.09.031. Epub 2010 Mar 16.

PMID:
20231075
4.

Disease control and ototoxicity using intensity-modulated radiation therapy tumor-bed boost for medulloblastoma.

Polkinghorn WR, Dunkel IJ, Souweidane MM, Khakoo Y, Lyden DC, Gilheeney SW, Becher OJ, Budnick AS, Wolden SL.

Int J Radiat Oncol Biol Phys. 2011 Nov 1;81(3):e15-20. doi: 10.1016/j.ijrobp.2010.11.081. Epub 2011 Apr 12.

PMID:
21481547
5.

Neuropsychological outcome following intensity-modulated radiation therapy for pediatric medulloblastoma.

Jain N, Krull KR, Brouwers P, Chintagumpala MM, Woo SY.

Pediatr Blood Cancer. 2008 Aug;51(2):275-9. doi: 10.1002/pbc.21580.

PMID:
18421716
6.

In regard to Huang et al.: Intensity-modulated radiation therapy for pediatric medulloblastoma: early report on the reduction of ototoxicity. IJROBP 2002;52:599-605.

Soomal R, Saran F, Brada M.

Int J Radiat Oncol Biol Phys. 2003 Mar 1;55(3):853; author reply 853-4. No abstract available.

PMID:
12573781
7.

Advantage of protons compared to conventional X-ray or IMRT in the treatment of a pediatric patient with medulloblastoma.

St Clair WH, Adams JA, Bues M, Fullerton BC, La Shell S, Kooy HM, Loeffler JS, Tarbell NJ.

Int J Radiat Oncol Biol Phys. 2004 Mar 1;58(3):727-34.

PMID:
14967427
8.

Initial experience using intensity-modulated radiotherapy for recurrent nasopharyngeal carcinoma.

Lu TX, Mai WY, Teh BS, Zhao C, Han F, Huang Y, Deng XW, Lu LX, Huang SM, Zeng ZF, Lin CG, Lu HH, Chiu JK, Carpenter LS, Grant WH 3rd, Woo SY, Cui NJ, Butler EB.

Int J Radiat Oncol Biol Phys. 2004 Mar 1;58(3):682-7.

PMID:
14967420
9.

Preliminary results of conformal radiation therapy for medulloblastoma.

Merchant TE, Happersett L, Finlay JL, Leibel SA.

Neuro Oncol. 1999 Jul;1(3):177-87.

10.

[Pilot study of conformal intensity modulated radiation therapy for localized prostate cancer].

Aillères N, Azria D, Thézenas S, Barbier N, Fenoglietto P, Delard R, Hay MH, Dubois JB.

Cancer Radiother. 2004 Apr;8(2):59-69. English, French.

PMID:
15063872
11.

Fatal pneumonitis associated with intensity-modulated radiation therapy for mesothelioma.

Allen AM, Czerminska M, Jänne PA, Sugarbaker DJ, Bueno R, Harris JR, Court L, Baldini EH.

Int J Radiat Oncol Biol Phys. 2006 Jul 1;65(3):640-5.

PMID:
16751058
12.

Whole pelvic radiotherapy for prostate cancer using 3D conformal and intensity-modulated radiotherapy.

Ashman JB, Zelefsky MJ, Hunt MS, Leibel SA, Fuks Z.

Int J Radiat Oncol Biol Phys. 2005 Nov 1;63(3):765-71.

PMID:
15913914
13.

Initial evaluation of treatment-related pneumonitis in advanced-stage non-small-cell lung cancer patients treated with concurrent chemotherapy and intensity-modulated radiotherapy.

Yom SS, Liao Z, Liu HH, Tucker SL, Hu CS, Wei X, Wang X, Wang S, Mohan R, Cox JD, Komaki R.

Int J Radiat Oncol Biol Phys. 2007 May 1;68(1):94-102. Epub 2007 Feb 22.

PMID:
17321067
14.

Intensity-modulated radiotherapy for soft tissue sarcoma of the thigh.

Hong L, Alektiar KM, Hunt M, Venkatraman E, Leibel SA.

Int J Radiat Oncol Biol Phys. 2004 Jul 1;59(3):752-9.

PMID:
15183478
15.

Sensorineural hearing loss after treatment of nasopharyngeal carcinoma: a longitudinal analysis.

Chan SH, Ng WT, Kam KL, Lee MC, Choi CW, Yau TK, Lee AW, Chow SK.

Int J Radiat Oncol Biol Phys. 2009 Apr 1;73(5):1335-42. doi: 10.1016/j.ijrobp.2008.07.034. Epub 2008 Oct 14.

PMID:
18922648
16.
17.

A comparison of intensity-modulated radiation therapy and concomitant boost radiotherapy in the setting of concurrent chemotherapy for locally advanced oropharyngeal carcinoma.

Lee NY, de Arruda FF, Puri DR, Wolden SL, Narayana A, Mechalakos J, Venkatraman ES, Kraus D, Shaha A, Shah JP, Pfister DG, Zelefsky MJ.

Int J Radiat Oncol Biol Phys. 2006 Nov 15;66(4):966-74.

PMID:
17145527
18.

Relative contributions of radiation and cisplatin-based chemotherapy to sensorineural hearing loss in head-and-neck cancer patients.

Hitchcock YJ, Tward JD, Szabo A, Bentz BG, Shrieve DC.

Int J Radiat Oncol Biol Phys. 2009 Mar 1;73(3):779-88. doi: 10.1016/j.ijrobp.2008.05.040. Epub 2008 Aug 15.

PMID:
18707819
19.

Beam path toxicities to non-target structures during intensity-modulated radiation therapy for head and neck cancer.

Rosenthal DI, Chambers MS, Fuller CD, Rebueno NC, Garcia J, Kies MS, Morrison WH, Ang KK, Garden AS.

Int J Radiat Oncol Biol Phys. 2008 Nov 1;72(3):747-55. doi: 10.1016/j.ijrobp.2008.01.012. Epub 2008 May 1.

PMID:
18455324
20.

Intensity-modulated radiation therapy for the treatment of oropharyngeal carcinoma: the Memorial Sloan-Kettering Cancer Center experience.

de Arruda FF, Puri DR, Zhung J, Narayana A, Wolden S, Hunt M, Stambuk H, Pfister D, Kraus D, Shaha A, Shah J, Lee NY.

Int J Radiat Oncol Biol Phys. 2006 Feb 1;64(2):363-73. Epub 2005 May 31.

PMID:
15925451

Supplemental Content

Support Center